MX2016001459A - Composiciones vacunales bivalentes y su uso para la terapia de tumores. - Google Patents

Composiciones vacunales bivalentes y su uso para la terapia de tumores.

Info

Publication number
MX2016001459A
MX2016001459A MX2016001459A MX2016001459A MX2016001459A MX 2016001459 A MX2016001459 A MX 2016001459A MX 2016001459 A MX2016001459 A MX 2016001459A MX 2016001459 A MX2016001459 A MX 2016001459A MX 2016001459 A MX2016001459 A MX 2016001459A
Authority
MX
Mexico
Prior art keywords
vaccine compositions
tumour
treating tumours
divalent vaccine
vssp
Prior art date
Application number
MX2016001459A
Other languages
English (en)
Inventor
Sánchez Ramírez Belinda
Yglesias Rivera Arianna
Gutiérrez Pérez Amelia
González Suárez Narjara
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51453541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016001459(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Publication of MX2016001459A publication Critical patent/MX2016001459A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen composiciones vacunales que combinan en igual proporción los dominios extracelulares de los receptores de factores de crecimiento Her1 y Her2 o fragmentos de estos y adicionalmente proteoliposomas de muy pequeña talla derivadas de proteínas de la membrana externa de Neisseria meningitidisy el gangliósido GM3 (VSSP-GM3), que están destinadas a la administración subcutánea; las composiciones descritas permiten inducir anticuerpos para el tratamiento de tumores malignos y presentan ventajas debido a que logran eliminar totalmente la masa tumoral y evitan la regresión del tumor a partir de la aparición de variantes resistentes.
MX2016001459A 2013-08-02 2014-08-01 Composiciones vacunales bivalentes y su uso para la terapia de tumores. MX2016001459A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CUP2013000110A CU24299B1 (es) 2013-08-02 2013-08-02 Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico
PCT/CU2014/000004 WO2015014327A1 (es) 2013-08-02 2014-08-01 Composiciones vacunales bivalentes y su uso para la terapia de tumores

Publications (1)

Publication Number Publication Date
MX2016001459A true MX2016001459A (es) 2017-01-05

Family

ID=51453541

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001459A MX2016001459A (es) 2013-08-02 2014-08-01 Composiciones vacunales bivalentes y su uso para la terapia de tumores.

Country Status (24)

Country Link
US (2) US20160166667A1 (es)
EP (1) EP3028714B1 (es)
JP (1) JP6479002B2 (es)
KR (1) KR20160018665A (es)
CN (1) CN105407916A (es)
AR (1) AR097172A1 (es)
AU (1) AU2014298978B2 (es)
CA (1) CA2916552C (es)
CL (1) CL2015003706A1 (es)
CU (1) CU24299B1 (es)
EA (1) EA034194B1 (es)
ES (1) ES2894075T3 (es)
HK (1) HK1220141A1 (es)
IL (1) IL243879B (es)
MX (1) MX2016001459A (es)
MY (1) MY194889A (es)
PE (1) PE20160174A1 (es)
PH (1) PH12016500224A1 (es)
SG (1) SG11201600084WA (es)
TN (1) TN2015000557A1 (es)
TW (1) TWI554281B (es)
UA (1) UA116154C2 (es)
WO (1) WO2015014327A1 (es)
ZA (1) ZA201601328B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018166542A1 (es) * 2017-03-15 2018-09-20 Centro De Inmunologia Molecular Método para el tratamiento de pacientes con carcinomas
US12019073B2 (en) 2017-03-15 2024-06-25 Centro De Inmunologia Molecular Method for the treatment of patients with carcinomas
CU24534B1 (es) 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4306697A1 (de) * 1993-03-04 1994-09-08 Merck Patent Gmbh Mittel und Verfahren zur immunologischen Bestimmung von Diphenhydramin und dessen Metaboliten
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
EP2639299A1 (en) * 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase

Also Published As

Publication number Publication date
EP3028714B1 (en) 2021-09-29
CN105407916A (zh) 2016-03-16
UA116154C2 (uk) 2018-02-12
EA034194B1 (ru) 2020-01-16
PE20160174A1 (es) 2016-04-20
HK1220141A1 (zh) 2017-04-28
IL243879B (en) 2019-09-26
TN2015000557A1 (en) 2017-04-06
MY194889A (en) 2022-12-21
PH12016500224A1 (en) 2016-05-16
BR112016002174A2 (pt) 2017-08-01
ES2894075T3 (es) 2022-02-11
EP3028714A1 (en) 2016-06-08
AU2014298978B2 (en) 2019-05-23
IL243879A0 (en) 2016-04-21
TWI554281B (zh) 2016-10-21
KR20160018665A (ko) 2016-02-17
AR097172A1 (es) 2016-02-24
TW201521765A (zh) 2015-06-16
SG11201600084WA (en) 2016-02-26
NZ716579A (en) 2021-10-29
JP2016525555A (ja) 2016-08-25
US20160166667A1 (en) 2016-06-16
CU20130110A7 (es) 2015-03-30
EA201690309A1 (ru) 2016-06-30
CU24299B1 (es) 2017-12-08
CL2015003706A1 (es) 2016-07-22
JP6479002B2 (ja) 2019-03-06
US20190275132A1 (en) 2019-09-12
ZA201601328B (en) 2017-11-29
CA2916552C (en) 2020-03-31
CA2916552A1 (en) 2015-02-05
WO2015014327A1 (es) 2015-02-05
AU2014298978A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
CL2016002359A1 (es) Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco
MX2020008977A (es) Formulaciones de anticuerpos de her2 subcutaneas.
PH12015500390A1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
PE20080663A1 (es) Terapia tumoral con una combinacion de anticuerpos anti-her2
NZ739448A (en) Transgene genetic tags and methods of use
PH12016500224A1 (en) Divalent vaccine compositions and the use thereof for treating tumors
MY152864A (en) Treatment of metastatic breast cancer
MX2015014431A (es) Monoterapia con glucopiranosil lipido a para usarse en el tratamieto del cancer.
MX2019014375A (es) Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.
MX2018006996A (es) Composiciones y metodos mejorados para la entrega viral de neoepitopos y usos de estos.
MX2016009284A (es) Construcciones dirigidas a receptor y sus usos.
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
MX2015008117A (es) Anticuerpos anti-h7cr.
NZ625758A (en) Method for treating breast cancer
MX2014013763A (es) Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer.
SG194735A1 (en) Compositions and methods for treating cancer
WO2017181099A8 (en) Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
SG194753A1 (en) Induction of il-12 using immunotherapy
PH12014501202A1 (en) Pharmaceutical compositions for the treatment of tumors expressing egfr and gm3 n-glycolyl ganglioside (neugcgm3)
MX2017001983A (es) Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos.
TH169737A (th) องค์ประกอบวัคซีนชนิดไดวาเลนต์และการใช้พวกมันสำหรับการบำบัดเนื้องอก
EA201991027A9 (ru) АНТИТЕЛА ПРОТИВ CD38 И СЛИТЫЕ БЕЛКИ С ОСЛАБЛЕННЫМ ИНТЕРФЕРОНОМ АЛЬФА-2b
EA201300693A1 (ru) Образованные из молекул антигенов, ассоциированных с предстательной железой, пептиды, связывающиеся с молекулами hla, и способы их применения

Legal Events

Date Code Title Description
FG Grant or registration